Impact of selective platelet inhibition in reducing cardiovascular risk - role of vorapaxar
Judy WM Cheng Department of Pharmacy Practice, MCPHS University, Boston, MA, USA Abstract: This article reviews the pharmacology, clinical efficacy, and safety of vorapaxar in reducing cardiovascular risk. Vorapaxar is a tricyclic himbacine-derived reversible inhibitor of platelet surface protease a...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2016-06-01
|
| Series: | Vascular Health and Risk Management |
| Subjects: | |
| Online Access: | https://www.dovepress.com/impact-of-selective-platelet-inhibition-in-reducing-cardiovascular-ris-peer-reviewed-article-VHRM |
| _version_ | 1818538024710963200 |
|---|---|
| author | Cheng JWM |
| author_facet | Cheng JWM |
| author_sort | Cheng JWM |
| collection | DOAJ |
| description | Judy WM Cheng Department of Pharmacy Practice, MCPHS University, Boston, MA, USA Abstract: This article reviews the pharmacology, clinical efficacy, and safety of vorapaxar in reducing cardiovascular risk. Vorapaxar is a tricyclic himbacine-derived reversible inhibitor of platelet surface protease activator receptor-1, which prevents thrombin from activating platelets. Two Phase III clinical trials and multiple subanalyses from the two trials with vorapaxar have been published. In patients with recent acute coronary syndrome, vorapaxar, when added to standard therapy, did not reduce the composite cardiovascular end point. In contrary, in a study of secondary prevention for patients with cardiovascular diseases, vorapaxar reduced the risk of cardiovascular death or ischemic events (myocardial infarction, stroke) in patients with stable atherosclerosis who were receiving standard therapy. Vorapaxar is approved in the US for use with aspirin and/or clopidogrel in the secondary prevention of thrombogenic cardiovascular events in stable patients with peripheral arterial disease or a history of myocardial infarction. Vorapaxar increases risk of bleeding and is contraindicated in patients with previous cerebrovascular events. It is essential to balance individual patient’s bleeding risk to any further cardiovascular benefits that they may get. Future investigation is also needed to evaluate use of vorapaxar with newer antiplatelet agents such as ticagrelor and cangrelor, as well as its role as monotherapy. Keywords: vorapaxar, protease activator receptor-1 antagonist, atherosclerotic disease |
| first_indexed | 2024-12-11T18:58:16Z |
| format | Article |
| id | doaj.art-ddb13e697f2343a3a8424bfcc9371435 |
| institution | Directory Open Access Journal |
| issn | 1178-2048 |
| language | English |
| last_indexed | 2024-12-11T18:58:16Z |
| publishDate | 2016-06-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Vascular Health and Risk Management |
| spelling | doaj.art-ddb13e697f2343a3a8424bfcc93714352022-12-22T00:54:05ZengDove Medical PressVascular Health and Risk Management1178-20482016-06-012016Issue 126326827427Impact of selective platelet inhibition in reducing cardiovascular risk - role of vorapaxarCheng JWMJudy WM Cheng Department of Pharmacy Practice, MCPHS University, Boston, MA, USA Abstract: This article reviews the pharmacology, clinical efficacy, and safety of vorapaxar in reducing cardiovascular risk. Vorapaxar is a tricyclic himbacine-derived reversible inhibitor of platelet surface protease activator receptor-1, which prevents thrombin from activating platelets. Two Phase III clinical trials and multiple subanalyses from the two trials with vorapaxar have been published. In patients with recent acute coronary syndrome, vorapaxar, when added to standard therapy, did not reduce the composite cardiovascular end point. In contrary, in a study of secondary prevention for patients with cardiovascular diseases, vorapaxar reduced the risk of cardiovascular death or ischemic events (myocardial infarction, stroke) in patients with stable atherosclerosis who were receiving standard therapy. Vorapaxar is approved in the US for use with aspirin and/or clopidogrel in the secondary prevention of thrombogenic cardiovascular events in stable patients with peripheral arterial disease or a history of myocardial infarction. Vorapaxar increases risk of bleeding and is contraindicated in patients with previous cerebrovascular events. It is essential to balance individual patient’s bleeding risk to any further cardiovascular benefits that they may get. Future investigation is also needed to evaluate use of vorapaxar with newer antiplatelet agents such as ticagrelor and cangrelor, as well as its role as monotherapy. Keywords: vorapaxar, protease activator receptor-1 antagonist, atherosclerotic diseasehttps://www.dovepress.com/impact-of-selective-platelet-inhibition-in-reducing-cardiovascular-ris-peer-reviewed-article-VHRMVorapaxarprotease activator receptor – 1 antagonistatherosclerotic disease |
| spellingShingle | Cheng JWM Impact of selective platelet inhibition in reducing cardiovascular risk - role of vorapaxar Vascular Health and Risk Management Vorapaxar protease activator receptor – 1 antagonist atherosclerotic disease |
| title | Impact of selective platelet inhibition in reducing cardiovascular risk - role of vorapaxar |
| title_full | Impact of selective platelet inhibition in reducing cardiovascular risk - role of vorapaxar |
| title_fullStr | Impact of selective platelet inhibition in reducing cardiovascular risk - role of vorapaxar |
| title_full_unstemmed | Impact of selective platelet inhibition in reducing cardiovascular risk - role of vorapaxar |
| title_short | Impact of selective platelet inhibition in reducing cardiovascular risk - role of vorapaxar |
| title_sort | impact of selective platelet inhibition in reducing cardiovascular risk role of vorapaxar |
| topic | Vorapaxar protease activator receptor – 1 antagonist atherosclerotic disease |
| url | https://www.dovepress.com/impact-of-selective-platelet-inhibition-in-reducing-cardiovascular-ris-peer-reviewed-article-VHRM |
| work_keys_str_mv | AT chengjwm impactofselectiveplateletinhibitioninreducingcardiovascularriskroleofvorapaxar |